カテゴリ： GlobalData, アメリカ, 企業調査

Atara Biotherapeutics Inc (ATRA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Atara Biotherapeutics Inc (ATRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9984
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：89
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company that develops T-cell based immunotherapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. The company is evaluating its lead candidate tabelecleucel, formerly ATA129, in Phase 3 for the treatment of epstein-barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline also encompasses an investigational candidate in Phase 2 clinical studies for refractory CMV infection; and two Phase 1 candidates for the treatment of MS; and a Phase 1 for the treatment of residual or relapsed leukemia after HCT, and for T-cell depleted HCT for patients with relapsed or refractory multiple myeloma plasma cell leukemia (PCL). It has presence in the US, Cayman Islands, Ireland, and Switzerland. Atara is headquartered in San Francisco, California, the US.

Atara Biotherapeutics Inc (ATRA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Atara Biotherapeutics Raises US$52 Million In Series B Financing 12
Nina Biotherapeutics Raises US$0.9 Million In Venture Financing 14
Pinta Biotherapeutics Raises US$6.3 Million In Venture Financing 15
Santa Maria Biotherapeutics Raises US$6.3 Million In Venture Financing 16
Santa Maria Biotherapeutics Raises US$18 Million In Venture Financing 17
Pinta Biotherapeutics Raises US$18 Million In Venture Financing 18
Nina Biotherapeutics Raises US$2.5 Million In Venture Financing 19
Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20
Partnerships 21
Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21
Atara Biotherapeutics Enters into Agreement with Merck 22
Licensing Agreements 23
Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23
Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27
Equity Offering 29
Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29
Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31
Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33
Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35
Atara Biotherapeutics Raises USD63 Million in IPO 37
Atara Biotherapeutics Inc – Key Competitors 39
Atara Biotherapeutics Inc – Key Employees 40
Atara Biotherapeutics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Nov 06, 2018: Atara Biotherapeutics announces third quarter 2018 financial results and recent operational progress 43
Aug 01, 2018: Atara Biotherapeutics announces second quarter 2018 financial results and recent operational progress 45
May 08, 2018: Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress 48
Feb 27, 2018: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress 50
Nov 09, 2017: Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights 54
Aug 07, 2017: Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights 56
May 04, 2017: Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights 58
Mar 09, 2017: Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights 60
Corporate Communications 61
Sep 11, 2018: Atara Biotherapeutics names Roy Baynes as Board Director 61
Jun 07, 2018: Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer 62
May 07, 2018: Atara Biotherapeutics Appoints Dietmar Berger As Global Head Of Research And Development 63
Apr 09, 2018: Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 64
Feb 21, 2018: Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018 65
May 10, 2017: Atara Biotherapeutics appoints new SVP and global commercial head 66
Product News 67
09/11/2017: Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 67
04/03/2017: Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer 68
Product Approvals 69
Jan 03, 2017: Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) 69
Clinical Trials 70
Jan 12, 2018: QIMR Berghofer-developed Immunotherapy for Multiple Sclerosis gets Green Light From US FDA to Proceed with Patient Enrollment at US sites for Global Phase 1 Clinical Study 70
Jan 02, 2018: Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 71
Dec 29, 2017: Atara Biotherapeutics Announces FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel In Patients With Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 72
Dec 11, 2017: Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder 74
Nov 01, 2017: Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers 76
Oct 25, 2017: Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190 78
Oct 19, 2017: Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis 80
Oct 16, 2017: Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis 81
Aug 22, 2017: Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer 82
Jul 31, 2017: Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis 83
May 10, 2017: Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team 84
Apr 20, 2017: Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis at the American Academy of Neurology Annual Meeting 2017 85
Mar 17, 2017: Atara Bio Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis 87
Mar 09, 2017: Atara Bio Provides Update on ATA-129 88
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89

List of Tables
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Atara Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Atara Biotherapeutics Raises US$52 Million In Series B Financing 12
Nina Biotherapeutics Raises US$0.9 Million In Venture Financing 14
Pinta Biotherapeutics Raises US$6.3 Million In Venture Financing 15
Santa Maria Biotherapeutics Raises US$6.3 Million In Venture Financing 16
Santa Maria Biotherapeutics Raises US$18 Million In Venture Financing 17
Pinta Biotherapeutics Raises US$18 Million In Venture Financing 18
Nina Biotherapeutics Raises US$2.5 Million In Venture Financing 19
Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20
Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21
Atara Biotherapeutics Enters into Agreement with Merck 22
Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23
Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27
Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29
Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31
Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33
Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35
Atara Biotherapeutics Raises USD63 Million in IPO 37
Atara Biotherapeutics Inc, Key Competitors 39
Atara Biotherapeutics Inc, Key Employees 40
Atara Biotherapeutics Inc, Other Locations 41
Atara Biotherapeutics Inc, Subsidiaries 41

List of Figures
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Atara Biotherapeutics Inc (ATRA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Canadian Utilities Limited
    Canadian Utilities Limited - Strategy, SWOT and Corporate Finance Report Summary Canadian Utilities Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Velatia SL：企業の戦略的SWOT分析
    Velatia SL - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Valeritas Inc：医療機器：M&Aディール及び事業提携情報
    Summary Valeritas Inc (Valeritas) is a medical technology company that develops and commercializes treatment solutions for diabetes. The company’s product includes V-Go insulin delivery device a wearable basal-bolus insulin delivery solution for patients with Type 2 diabetes. It also provides V-Go l …
  • PanaHome Corp：企業の戦略的SWOT分析
    PanaHome Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • NLC India Ltd：発電所・企業SWOT分析
    NLC India Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • The Broad Institute Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary The Broad Institute Inc (Broad Institute), a subsidiary of The Broad Foundation is a non-profit research organization that conducts genomic research for treatment of human diseases. The organization transforms medicine by utilizing systematic approaches in biological sciences, to speed up th …
  • Molecular Warehouse Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Molecular Warehouse Ltd (Molecular Warehouse) is a developer of proteins for diagnostic and therapeutic use. The company helps prevent diseases by empowering people with molecular diagnostics. Its synthetic biology techniques enabled it to reengineer glucose dehydrogenase, and enzymes found …
  • Dongbu HiTek Co., Ltd. (000990)：企業の財務・戦略的SWOT分析
    Dongbu HiTek Co., Ltd. (000990) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Keysight Technologies Inc：企業の戦略・SWOT・財務情報
    Keysight Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary Keysight Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Chang Hwa Commercial Bank, Ltd.：企業の戦略・SWOT・財務情報
    Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Mgm China Holdings Ltd：企業の戦略・SWOT・財務分析
    Mgm China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Mgm China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • United Utilities Group PLC：企業の戦略・SWOT・財務分析
    United Utilities Group PLC - Strategy, SWOT and Corporate Finance Report Summary United Utilities Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Synedgen Inc：医療機器：M&Aディール及び事業提携情報
    Summary Synedgen Inc (Synedgen) is a biotechnology company that discovers and develops polysaccharide-based drugs, which enhance and mimic the innate immune system. The company’s pipeline products include SYGN305, SYGN399, SYGN303, SYGN313 and SYGN309. Synedgen develops products for the treatment of …
  • Hansen Technologies Ltd (HSN)：企業の財務・戦略的SWOT分析
    Summary Hansen Technologies Ltd (Hansen Technologies) is a technology company that offers customer care, billing, and meter data management software solutions. The company provides outsourcing services such as facilities management, support center, consulting, host management, business continuity, i …
  • SoftBank Group Corp (9984)：電力：M&Aディール及び事業提携情報
    Summary SoftBank Group Corp (SoftBank) is a provider of integrated telecommunications services. The company is involved in various businesses related to the information industry with presence in fixed-line telecommunications, mobile communications, internet services, and distribution. It offers serv …
  • Reliance Capital Ltd：企業の戦略・SWOT・財務分析
    Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report Summary Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Atlantic Power Corporation：企業の発電所・SWOT分析2018
    Atlantic Power Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Sky plc (SKY)：企業の財務・戦略的SWOT分析
    Sky plc (SKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Northrop Grumman Technical Services Inc.：企業の戦略・SWOT・財務分析
    Northrop Grumman Technical Services Inc. - Strategy, SWOT and Corporate Finance Report Summary Northrop Grumman Technical Services Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Preem AB：企業の戦略的SWOT分析
    Preem AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆